ALNY 8-K Current Reports
ALNYLAM PHARMACEUTICALS, INC. - 280 current reports
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jul 30, 2026)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K on July 30, 2026, primarily to announce its financial results for the second quarter ended June 30, 2026. While the filing itself does not contain the detailed financial figures, it directs investors to an accompanying press release (Exhibit 99.1) for the full earnings announcement. Investors should refer to this press release for critical information regarding the company's performance, revenue, profitability, and any forward-looking guidance.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (May 27, 2026)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report detailing key governance and shareholder decisions made at its recent Annual Meeting and a board expansion. The company has appointed Dr. Benjamin F. Cravatt to its Board of Directors as a Class III director, effective June 1, 2026, filling a newly created vacancy and also serving on the Science and Technology Committee. This appointment is accompanied by a standard non-employee director compensation package, including an annual cash retainer and initial and ongoing equity awards, designed to align director interests with shareholders. Furthermore, the filing provides an update on the outcomes of the Annual Meeting, including the re-election of three Class I directors, a strong advisory vote of approval for executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026. These events reflect the company's commitment to robust corporate governance and shareholder engagement.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Apr 30, 2026)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on April 30, 2026, to disclose its financial results for the first quarter ended March 31, 2026. While the report itself provides minimal operational detail, it serves as an official notification that the company has issued a press release containing its quarterly financial performance. Investors should refer to Exhibit 99.1, the furnished press release, for the specific financial data and operational updates for the period. This filing indicates that Alnylam is adhering to its reporting schedule and providing investors with timely, albeit summarized, financial information through an accompanying press release. The key takeaway for investors is to access and review the press release (Exhibit 99.1) for comprehensive details regarding Alnylam's Q1 2026 performance. This includes revenue figures, profitability, any significant developments in its drug pipeline, and forward-looking guidance. The 8-K filing serves as the formal channel for this information, emphasizing the importance of consulting the supplementary materials provided for a complete understanding of the company's financial health and strategic progress.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Mar 4, 2026)
Alnylam Pharmaceuticals, Inc. announced on March 4, 2026, the grant of a significant special equity award to its CEO, Yvonne Greenstreet, M.D., M.B.A. This award, effective March 2, 2026, is designed to retain and incentivize Dr. Greenstreet over the next several years, aligning her compensation with substantial future stock price appreciation. The Board recognizes her critical role in the company's recent successes, including nearly 100% stockholder return, key product launches like AMVUTTRA, and the achievement of the 'Alnylam P5x25' goals, including profitability in 2025. The special award is entirely performance-based, with vesting contingent upon the company's stock price reaching specific, ambitious thresholds by December 31, 2029. The award has a target value of $18.0 million, represented by 55,373 performance share units. The terms stipulate that 50% of the target shares vest if the average stock price reaches $500, and 200% vest if it reaches $800, with linear interpolation for performance in between. Importantly, no shares will vest if the stock price does not reach a baseline threshold of $500, which is above the all-time high at the grant date. This structure strongly links executive compensation to significant long-term value creation for shareholders.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 12, 2026)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 12, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily serves as a vehicle to furnish the accompanying press release containing detailed financial and operational performance information. Investors should refer to Exhibit 99.1, the press release itself, for the substantive details of these results, as this 8-K filing does not contain the specific figures but rather points to the document where they can be found. The company is utilizing this filing to meet its disclosure obligations regarding material events, specifically the release of its earnings. While the 8-K itself is brief, the furnished press release (Exhibit 99.1) is expected to contain crucial information regarding Alnylam's revenue performance, profitability, key product sales (such as ONPZEO, GIVLAARI, and OXLUMO), pipeline advancements, and any forward-looking guidance for the upcoming fiscal year. Investors will be keen to understand the company's financial health, operational execution, and strategic direction as outlined in the earnings announcement. It is imperative for stakeholders to review the content of the press release for a comprehensive understanding of Alnylam's recent performance and future outlook.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 12, 2026)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K to announce its new five-year strategic plan, "Alnylam 2030." This plan outlines the company's vision and direction for the next five years, aiming to drive growth and innovation in the RNAi therapeutics space. In conjunction with the strategy, Alnylam provided preliminary unaudited financial results for the fourth quarter and full year 2025. The company anticipates approximately $995 million in global net product revenues for Q4 2025 and $2,987 million for the full year 2025, driven by its key products AMVUTTRA®, ONPATTRO®, GIVLAARI®, and OXLUMO®. Alnylam also offered initial product and pipeline goals for 2026, including combined net product revenue guidance.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Dec 11, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) announced on December 11, 2025, that it has entered into agreements to repurchase approximately $34.4 million in aggregate principal amount of its 1.00% convertible senior notes due 2027. The total cost for this repurchase is approximately $51.9 million, including accrued interest. This action is expected to reduce the outstanding principal amount of these notes to approximately $362.8 million upon closing. This move suggests Alnylam is actively managing its debt obligations and capital structure. While the financial impact on the company's balance sheet and cash flow will be immediate, the forward-looking statements indicate potential risks related to execution of their strategy, drug development, regulatory approvals, and market performance. Investors should monitor the company's cash position and ongoing debt management strategies.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Dec 3, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) announced a change in its Board of Directors composition via an 8-K filing. Michael W. Bonney and Carolyn Bertozzi, Ph.D. have resigned from the Board, effective December 2, 2025. The company explicitly states that these resignations were not due to any disagreements with the company's operations, policies, or practices. Following these departures, the Board size has been reduced from eleven to ten directors. To fill the vacancy and add expertise, the Board has elected Stuart A. Arbuckle as a non-employee director, effective January 5, 2026. Mr. Arbuckle's appointment is accompanied by details of his compensation, which includes an annual cash retainer, an initial stock option grant with a significant fair value, and eligibility for future annual equity awards. This move aims to strengthen the Board's governance and strategic oversight as Alnylam continues its operations.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 30, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed a Current Report on Form 8-K to announce its financial results for the quarter ended September 30, 2025. The report primarily serves as a vehicle to furnish the accompanying press release, which contains the detailed financial outcomes for the period. Investors should refer to the press release (Exhibit 99.1) for the specific revenue, earnings, and other key financial metrics. While this 8-K filing itself does not contain the detailed financial data, it signifies the official public disclosure of Alnylam's performance for the third quarter of 2025. The company's forward-looking statements within the press release, if any, would be crucial for assessing future prospects, but are not directly presented in the 8-K filing's core text. Investors are encouraged to review the furnished press release for a comprehensive understanding of the company's operational and financial standing as of and for the quarter ended September 30, 2025.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Oct 3, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) has announced the execution of a new Credit Agreement, establishing a $500.0 million revolving line of credit set to mature on September 30, 2030. This facility, with a $150.0 million letter of credit sublimit, is intended to support working capital and general corporate purposes. The agreement allows for potential incremental borrowings, subject to customary conditions, and provides flexibility in interest rate options including base rate, Term SOFR, or an alternative currency rate, with margins tied to the Company's Total Leverage Ratio. The credit facility is secured by substantially all of Alnylam's and its material domestic subsidiaries' assets, with guarantees from these subsidiaries. Key financial covenants include maintaining a Total Net Leverage Ratio of no more than 3.75:1.00 (with a potential 0.50:1.00 step-up post-Material Acquisition) and an interest coverage ratio of at least 3.00:1.00. The maturity date could be accelerated under specific conditions related to 'Springing Maturity Debt.' This new credit line provides Alnylam with significant financial flexibility and resources to fund its ongoing operations and strategic initiatives.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Sep 12, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) announced the completion of a significant financing event through the issuance of $661.25 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2028. These notes, issued at a substantial premium to the company's stock price, offer flexibility for conversion into Alnylam's common stock under specific conditions, with the company retaining the option to settle conversions in cash, stock, or a combination thereof. The company also strategically entered into capped call transactions, costing approximately $35.3 million, intended to mitigate potential dilution and offset cash outlays associated with note conversions. In conjunction with this offering, Alnylam also repurchased approximately $637.8 million of its existing 1.00% convertible senior notes due 2027 for a total cost of approximately $1,105.8 million. This move indicates a proactive approach to managing its capital structure and debt obligations, potentially reducing future interest expenses and optimizing its financial position. Investors should monitor the conversion rate, potential dilution from stock issuance, and the effectiveness of the capped call strategy.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Sep 10, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) announced on September 8th and 9th, 2025, the commencement and subsequent pricing of a proposed offering of convertible senior notes due 2028. This move suggests the company is looking to raise capital through debt financing, which is a common strategy for growth-stage biotechnology firms to fund research, development, and potential commercialization efforts without immediate dilution to existing shareholders. Investors should pay close attention to the terms of these convertible notes, including the principal amount, coupon rate, conversion price, and maturity date, as these will impact the company's future capital structure and potential equity dilution. The offering is being conducted under Rule 144A, targeting qualified institutional buyers, indicating a significant transaction. While the filings do not disclose the exact amount raised, the issuance of convertible notes is a key event that could influence Alnylam's financial flexibility and strategic investments moving forward.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jul 31, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on July 31, 2025, to announce its financial results for the second quarter ended June 30, 2025. The report primarily includes a press release detailing these results. While the specific financial figures are not detailed within the 8-K text itself, investors should refer to the furnished press release (Exhibit 99.1) for comprehensive information regarding the company's performance, revenue, profitability, and any forward-looking guidance provided for the remainder of the fiscal year. This filing serves as the official notification of the company's quarterly performance. Investors are encouraged to review the press release to understand key operational updates, product pipeline progress, and any strategic developments that may have influenced the financial outcomes. The information provided in this 8-K, specifically the financial results, is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same legal implications as formally filed information.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jun 18, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) announced significant organizational changes within its Research and Development (R&D) functions via an 8-K filing on June 18, 2025. The company has combined its Research and Early Development function with its Development function into a single R&D organization to streamline operations and potentially accelerate pipeline progression. This strategic move is accompanied by key leadership adjustments and updated compensation packages for senior R&D executives. Specifically, Dr. Pushkal Garg has been appointed Executive Vice President, Chief Research and Development Officer, consolidating leadership over the newly integrated R&D division. Dr. Kevin Fitzgerald's role has been expanded to include external innovation alongside his existing responsibilities as Chief Scientific Officer. These appointments are supported by revised compensation structures, including salary increases, incentive programs, and a substantial equity grant for Dr. Fitzgerald, signaling the company's investment in and commitment to its top R&D talent as it navigates this organizational shift. Investors should monitor how this R&D integration impacts clinical trial progress and innovation output.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Bylaw Amendment (May 13, 2025)
This Form 8-K filing from Alnylam Pharmaceuticals, Inc. details the outcomes of their 2025 Annual Meeting of Stockholders held on May 8, 2025. Key to investors is the stockholder approval and subsequent filing of an amendment to the Company's Certificate of Incorporation to allow for officer exculpation. This change aims to further protect the company's officers from certain liabilities, a common governance enhancement. Additionally, the filing reports on the re-election of four Class III directors, the approval of the Second Amended and Restated 2018 Stock Incentive Plan, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025. The approval of executive compensation in a non-binding advisory vote also indicates stockholder sentiment on executive remuneration. These outcomes generally reflect stable corporate governance and continued investor confidence in the company's leadership and operational structure. The re-election of directors and approval of incentive plans suggest a continuity in strategy and management oversight. The focus on officer exculpation, while a governance matter, is often viewed positively by management and potentially by investors as it can aid in attracting and retaining qualified leadership by mitigating personal financial risk related to their service. The ratification of the auditor also signals confidence in the company's financial reporting processes.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (May 1, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 1, 2025, announcing its financial results for the quarter ended March 31, 2025. While the 8-K itself primarily serves as a notification of the release and doesn't contain the detailed financial data, it references a press release (Exhibit 99.1) which holds the crucial operational and financial condition information for investors. This filing indicates that key performance metrics, revenue figures, and any significant updates on the company's pipeline or commercial performance for the first quarter of 2025 were disclosed in the accompanying press release.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Mar 21, 2025)
Alnylam Pharmaceuticals, Inc. has announced a significant regulatory milestone with the U.S. Food and Drug Administration's (FDA) approval of its supplemental new drug application for AMVUTTRA® (vutrisiran). This expanded indication allows AMVUTTRA® to treat the cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients. The approval is specifically for its ability to reduce key cardiovascular outcomes, including mortality, hospitalizations, and urgent visits related to heart failure. This FDA approval represents a major expansion of AMVUTTRA®'s therapeutic reach into a serious and progressive condition where unmet medical needs exist. The drug's demonstrated efficacy in reducing cardiovascular morbidity and mortality in ATTR-CM patients is a crucial development for the company and the patient community. Investors should view this as a positive catalyst, potentially driving significant revenue growth and solidifying Alnylam's position in the rare genetic disease market, particularly in amyloidosis.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Mar 5, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) announced on March 5, 2025, that Dr. Phillip A. Sharp will be retiring from the Board of Directors, effective May 8, 2025. This departure is not attributed to any disagreements with the company and is a planned retirement. Dr. Sharp's continued involvement with Alnylam is assured as he will remain a member of the company's Scientific Advisory Board, indicating a smooth transition and ongoing commitment to the company's scientific endeavors.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (Feb 13, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on February 13, 2025, to announce its financial results for the fourth quarter and full year ended December 31, 2024. While the 8-K itself does not contain the detailed financial figures, it references an accompanying press release (Exhibit 99.1) which will hold the comprehensive performance data and management's commentary. Investors should refer to this press release for specifics on revenue, profitability, and any forward-looking guidance. This filing serves as Alnylam's official notification of its recent financial performance. Key areas of interest for investors will likely include the performance of its commercial products, pipeline advancements, and the company's overall financial health as it moves into the new fiscal year. The press release will provide the critical details to assess Alnylam's execution against its strategic objectives and its potential for future growth.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 13, 2025)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on January 13, 2025, providing preliminary financial results for the fourth quarter and full year 2024, alongside initial guidance for 2025. The company reported approximately $451 million in preliminary fourth-quarter 2024 global net product revenues and $1,646 million for the full year 2024, driven by its key therapies ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. These preliminary figures offer investors an early look at the company's performance ahead of its complete financial results announcement in February 2025. Alnylam has also set forth its product and pipeline goals for 2025, including revenue guidance and non-GAAP operating income guidance, signaling its strategic direction and financial outlook for the upcoming year. Investors should note that these preliminary results are unaudited and subject to adjustments.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (Oct 31, 2024)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on October 31, 2024, to report its financial results for the quarter ended September 30, 2024. The filing includes a press release detailing the company's performance. While specific financial figures are not detailed within the 8-K itself, it serves as the official announcement mechanism for these key results, which are crucial for investors to assess the company's operational and financial health. Investors should refer to the furnished press release (Exhibit 99.1) for a comprehensive understanding of Alnylam's third-quarter 2024 performance, including revenue, profitability, and any updates on their drug pipeline and commercialization efforts. This report signifies a standard disclosure event for publicly traded companies, providing timely information on their ongoing business activities.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (Aug 1, 2024)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 1, 2024, to report its financial results for the second quarter ended June 30, 2024. The key takeaway from this filing is the announcement of these financial results, which were detailed in an accompanying press release furnished as an exhibit. Investors should refer to this press release for specific financial performance metrics, revenue figures, profitability, and any updates on the company's drug pipeline and commercial progress. While the 8-K itself does not contain the detailed financial data, it serves as the official notification of the earnings release. Investors and interested parties are directed to the furnished press release (Exhibit 99.1) for a comprehensive understanding of Alnylam's performance during the second quarter. This typically includes updates on key products, research and development milestones, and forward-looking statements that are crucial for evaluating the company's current standing and future prospects.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (May 20, 2024)
Alnylam Pharmaceuticals, Inc. (ALNY) held its 2024 Annual Meeting of Stockholders on May 16, 2024, with a filing on May 20, 2024, detailing the outcomes of key votes. The meeting saw the overwhelming re-election of four Class II directors: Dennis A. Ausiello, M.D., Olivier Brandicourt, M.D., Peter N. Kellogg, and David E.I. Pyott, each receiving substantial support from shareholders to serve until the 2027 annual meeting. This demonstrates continued confidence in the board's leadership and strategic direction. Furthermore, Alnylam's stockholders overwhelmingly approved the compensation of the company's named executive officers in a non-binding advisory vote, indicating shareholder alignment with the company's executive compensation policies. The appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2024, was also overwhelmingly ratified, reinforcing the company's commitment to robust financial oversight and transparent reporting. The strong voting results across these critical matters suggest a stable and supportive shareholder base.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (May 2, 2024)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 2, 2024, to announce its financial results for the quarter ended March 31, 2024. While the 8-K itself primarily references a furnished press release for the detailed financial information, this filing indicates the company is providing its Q1 2024 operational and financial update to the market. Investors should refer to the press release (Exhibit 99.1) for the specific financial and operational details of the first quarter. This filing serves as the official notification mechanism for the release of this information, highlighting the company's ongoing financial performance and operational status. The information is furnished, not filed, meaning it is provided for disclosure purposes but does not carry the same legal implications under Section 18 of the Exchange Act.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Mar 4, 2024)
This 8-K filing from Alnylam Pharmaceuticals, Inc. details the separation of its former Executive Vice President, Chief Legal Officer, and Secretary, Indrani L. Franchini, effective March 1, 2024. The company has entered into a separation and release agreement with Ms. Franchini, outlining the terms of her departure and ongoing engagement as a consultant. This agreement is significant for investors as it clarifies the financial and operational implications of a key executive's exit.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 15, 2024)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 15, 2024, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2023. The key takeaway for investors is the release of this financial data, which is contained within an attached press release (Exhibit 99.1). This filing serves as the official notification of their latest performance metrics, including revenue, profitability, and potentially forward-looking statements or guidance, though the specifics of these results are detailed in the furnished press release rather than the 8-K itself. Investors should carefully review the accompanying press release for comprehensive details on Alnylam's financial condition and operational results for the period. This includes understanding the company's revenue generation, cost management, and any significant developments impacting their financial outlook. The 8-K filing itself acts as a regulatory gateway to this crucial financial information, highlighting the company's commitment to timely disclosure of material updates.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jan 19, 2024)
This 8-K filing from Alnylam Pharmaceuticals, Inc. announces the upcoming departure of its Executive Vice President, Chief Legal Officer, and Secretary, Indrani L. Franchini, effective March 1, 2024. Ms. Franchini will transition from her role, and a formal separation agreement outlining severance and transition terms is expected to be finalized by her Separation Date. Investors should monitor future filings for details on the successor and any impact on the company's legal and corporate governance functions. While this filing primarily pertains to an executive departure, it's important for investors to note that significant leadership changes can sometimes signal shifts in strategy or internal focus. However, the provided details are limited, and no immediate operational or financial impacts are detailed within this specific report. The filing also includes standard exhibit information.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 8, 2024)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report announcing preliminary financial results for the fourth quarter and full year 2023. Key takeaways include strong preliminary net product revenues for their key therapies, ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. The company reported approximately $346 million in global net product revenues for Q4 2023 and an impressive $1,241 million for the full year 2023. Furthermore, Alnylam concluded 2023 with a robust cash position, reporting approximately $2.4 billion in cash, cash equivalents, and marketable securities as of December 31, 2023. These preliminary figures provide an early look at the company's performance ahead of their full financial results announcement scheduled for February 2024, indicating positive momentum in revenue generation and a healthy balance sheet.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 2, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K on November 2, 2023, to report its financial results for the third quarter ended September 30, 2023. While the filing itself does not contain the detailed financial figures, it references a furnished press release (Exhibit 99.1) that provides this information. Investors should refer to this press release for specifics on revenue, profitability, and other key financial metrics. This announcement is crucial for understanding the company's recent performance and its trajectory moving forward. The key takeaway for investors is that Alnylam is providing an update on its financial condition and operational results for the most recent quarter. The 8-K serves as the official notification of this release, directing stakeholders to the accompanying press release for the comprehensive data. It's important to note that the information furnished in this 8-K, including the press release, is not considered "filed" for certain regulatory purposes, which is standard practice for such announcements.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Oct 10, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) announced on October 9, 2023, that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for patisiran. The sNDA sought approval for patisiran, an RNA interference (RNAi) therapeutic, for the treatment of the cardiomyopathy associated with transthyretin-mediated (ATTR) amyloidosis. This development is a setback for Alnylam's efforts to expand the label of patisiran into this significant indication.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Sep 28, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) has reported a change in its Board of Directors structure. Marsha H. Fanucci will be resigning from the Board effective September 29, 2023. This departure is explicitly stated as not being due to any disagreements regarding the company's operations, policies, or practices, which suggests a smooth transition. Following Ms. Fanucci's resignation, Peter N. Kellogg is set to assume the role of Chair of the Audit Committee. The Board has confirmed Mr. Kellogg's qualification as an "audit committee financial expert," a key designation for financial oversight. Concurrently, the size of the Board will be reduced from thirteen to twelve members. These changes, while administrative, are important for investors to note regarding board composition and audit committee leadership.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 3, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 3, 2023, primarily announcing its financial results for the quarter ended June 30, 2023. While the 8-K references a press release with these financial details, the filing itself focuses on a significant leadership transition. Akshay K. Vaishnaw, M.D., Ph.D., is transitioning from his role as President to a part-time position as Chief Innovation Officer, effective October 2, 2023. This transition involves specific compensation and severance arrangements detailed in a Letter Agreement. Dr. Vaishnaw will continue with the company in a new capacity, focusing on innovation, while his compensation structure, including base salary and bonus targets, has been adjusted. The agreement also outlines provisions for termination and potential change-in-control scenarios, including continued equity vesting, which investors should note for potential impacts on compensation expenses and leadership continuity.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jul 26, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) has entered into a significant strategic collaboration with Roche Basel and Genentech, Inc. (collectively, Roche) for the joint development and commercialization of zilebesiran, an siRNA therapeutic targeting liver-expressed angiotensinogen (AGT). This agreement grants Roche co-exclusive rights in the United States and exclusive rights outside the U.S. for development and commercialization. This deal provides Alnylam with a substantial upfront payment of $310 million and positions the company to receive up to an additional $2.5 billion in contingent milestone payments. While Alnylam will retain marketing authorization in the U.S. and share profits and losses (50/50) within the U.S., Roche will handle marketing and bear the costs in the Roche Territory, paying Alnylam tiered, low double-digit royalties. This collaboration signifies a key step for Alnylam in advancing zilebesiran, potentially de-risking development and expanding its global reach.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Jun 30, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant event for its flagship product, ONPATTRO® (patisiran). On June 30, 2023, the company disclosed that the U.S. Food and Drug Administration (FDA) has scheduled a Cardiovascular and Renal Drugs Advisory Committee meeting for September 13, 2023. This meeting will focus on the supplemental New Drug Application (sNDA) for ONPATTRO® seeking approval for the treatment of the cardiomyopathy associated with transthyretin-mediated (ATTR) amyloidosis.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (May 23, 2023)
This 8-K filing from Alnylam Pharmaceuticals, Inc. details the outcomes of their Annual Meeting of Stockholders held on May 18, 2023. The key takeaways for investors are the overwhelmingly positive shareholder support for the company's board of directors, executive compensation, and auditor ratification. All proposed director nominees received substantial 'for' votes, indicating shareholder confidence in the current leadership. Furthermore, shareholders approved executive compensation in a non-binding vote and recommended an annual frequency for such votes, aligning with management's intent. The ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023 also received strong endorsement. These results suggest a stable governance environment and shareholder alignment with the company's strategic direction and financial oversight, which are crucial factors for investor confidence and long-term value creation.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 4, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 4, 2023, primarily to report its financial results for the quarter ended March 31, 2023. The key takeaway for investors is the release of these Q1 2023 financial and operational updates, which are detailed in the accompanying press release (Exhibit 99.1). This filing serves as the official channel for disseminating these important performance metrics. While the 8-K itself does not contain the detailed financial figures, it directs investors to the furnished press release for comprehensive information. Investors should review Exhibit 99.1 to understand Alnylam's revenue, earnings, and any significant operational developments or guidance changes announced during the period. It's important to note that the information provided in this 8-K, specifically Item 2.02, is furnished and not deemed "filed" for certain regulatory purposes, meaning it doesn't automatically become part of other SEC filings unless specifically incorporated.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Mar 8, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) announced a change to its Board of Directors through a Form 8-K filing on March 8, 2023. The company expanded its board size from twelve to thirteen members and elected Peter N. Kellogg as a new Class II director. Mr. Kellogg's term will expire at the 2024 annual meeting of stockholders, and he is expected to join the Audit Committee, a critical oversight function for financial reporting and internal controls. This appointment brings new expertise to the board, and the filing details Mr. Kellogg's compensation package, which includes an annual cash fee and a significant stock option grant. This compensation structure aligns with standard practices for non-employee directors and aims to incentivize long-term value creation for shareholders. Investors should note the addition of a director and the associated compensation as a governance-related event.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 23, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) announced its financial results for the fourth quarter and full year ended December 31, 2022, via an 8-K filing on February 23, 2023. The filing primarily serves as a vehicle to furnish the press release containing these results. Investors should note that the information furnished in this Item 2.02 is not considered 'filed' for regulatory purposes, meaning it does not carry the same legal liabilities as traditional filings. However, the press release itself is expected to contain key financial performance indicators and strategic updates relevant to the company's ongoing operations and future outlook. While the 8-K itself does not contain the detailed financial figures, it directs investors to Exhibit 99.1, the press release, for the specific results. Investors are encouraged to review this press release for comprehensive information regarding revenue, profitability, cash position, and any forward-looking guidance or significant operational developments disclosed by Alnylam. This filing is a standard procedure for disseminating earnings information promptly to the market.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 9, 2023)
Alnylam Pharmaceuticals, Inc. has reported preliminary financial results for the fourth quarter and full year 2022, demonstrating continued revenue growth from its key therapeutic products. For the full year 2022, global net product revenues are estimated to be approximately $894 million, with fourth quarter revenues reaching approximately $262 million. These figures encompass revenues from ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, indicating strong commercial uptake and progress in market penetration for these treatments. Furthermore, the Company anticipates a robust financial position, with preliminary cash, cash equivalents, and marketable securities of approximately $2.2 billion as of December 31, 2022. This healthy cash balance provides Alnylam with significant financial flexibility for future research and development, potential business development opportunities, and continued commercial expansion. Investors should note that these results are preliminary and unaudited, with final audited results expected in February 2023.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jan 6, 2023)
Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant change in its Board of Directors structure, effective January 5, 2023. The Board size was expanded to twelve, and Dr. Carolyn R. Bertozzi was elected as a new Class III director, with her term set to expire at the 2025 annual meeting of stockholders. Dr. Bertozzi's appointment brings new expertise to the board, and her compensation as a non-employee director includes an annual cash fee of $55,000 and initial stock options valued at $600,000, with further annual stock awards anticipated. This move signifies the company's commitment to strengthening its governance and leveraging external expertise. Furthermore, the company disclosed leadership transitions within its Board. Michael W. Bonney transitioned from his role as Executive Chair to serve as a regular director. Concurrently, Amy W. Schulman has been appointed as the new Chair of the Board. These changes, detailed in a press release furnished with the filing, indicate a strategic shift in board leadership and governance responsibilities, aiming to enhance operational oversight and strategic direction.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 27, 2022)
Alnylam Pharmaceuticals, Inc. announced its financial results for the third quarter ended September 30, 2022, on October 27, 2022. This 8-K filing primarily serves to furnish the press release detailing these results, which is crucial for investors seeking updates on the company's performance and financial standing. While the filing itself is brief, the attached press release (Exhibit 99.1) contains the substantive financial and operational information.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Sep 16, 2022)
Alnylam Pharmaceuticals, Inc. (ALNY) announced on September 16, 2022, the successful pricing and closing of a $1.035 billion offering of 1.00% Convertible Senior Notes due 2027. This financing activity significantly impacts the company's capital structure and future financial flexibility. The net proceeds are being utilized for a combination of strategic debt repayment and mitigating potential equity dilution. A substantial portion of the proceeds, approximately $762.0 million, was used to repay and terminate an existing credit agreement. This deleveraging move strengthens the balance sheet and reduces interest expenses. Concurrently, the company entered into capped call transactions, costing approximately $118.6 million, designed to offset potential dilution to common stockholders upon conversion of the new notes. This structure aims to protect shareholder value while enabling the company to access capital through convertible debt.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Sep 13, 2022)
Alnylam Pharmaceuticals, Inc. (ALNY) filed a Form 8-K on September 13, 2022, to report on its proposed offering of convertible senior notes due 2027. The filing includes two press releases: one announcing the commencement of the offering on September 12, 2022, and another detailing the pricing of the offering on September 13, 2022. These notes were offered to qualified institutional buyers under Rule 144A. This financing activity indicates Alnylam's strategy to raise capital, potentially to fund ongoing research and development, clinical trials, or general corporate purposes. While the specific use of proceeds isn't detailed in this 8-K, convertible notes offer a way to secure funding with the possibility of conversion into equity in the future, which could dilute existing shareholders if conversion occurs. Investors should review the full press releases for details on the terms of the notes, including interest rates, maturity dates, and conversion features, as well as any stated use of funds.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Aug 24, 2022)
Alnylam Pharmaceuticals, Inc. (ALNY) announced a key addition to its Board of Directors, electing Dr. Elliott Sigal to fill a newly created vacancy, expanding the Board to eleven members. Dr. Sigal's appointment is effective August 22, 2022, and he will serve as a Class I director with his term expiring at the 2023 annual meeting of stockholders. His election is a significant development as the company continues to grow and navigate the complex biotechnology landscape. Dr. Sigal's compensation as a non-employee director includes an annual cash fee of $55,000 and an initial stock option grant valued at $600,000, vesting over three years. He is also eligible for future annual stock option awards. This compensation structure aligns with industry practices for attracting experienced leadership to the board and signals the company's commitment to leveraging external expertise to drive strategic initiatives and enhance shareholder value.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jul 28, 2022)
Alnylam Pharmaceuticals, Inc. (ALNY) announced its financial results for the second quarter ended June 30, 2022, on July 28, 2022. This 8-K filing primarily serves to furnish the press release containing these results. While the specific financial figures are not detailed within the 8-K itself, the press release, incorporated by reference, would contain key performance indicators such as revenue, net income/loss, and earnings per share. Investors should refer to the furnished press release (Exhibit 99.1) for the detailed financial performance and any forward-looking statements made by the company. This filing does not introduce any new material events beyond the earnings announcement. As is standard for earnings releases furnished under Item 2.02, the information is not deemed "filed" for purposes of certain securities laws, meaning it does not carry the same liabilities as formally filed documents unless specifically incorporated into other filings. Investors should use this information as a starting point and delve into the press release for a comprehensive understanding of Alnylam's recent financial standing and operational updates.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Jun 14, 2022)
Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant development on June 13, 2022, with the U.S. Food and Drug Administration (FDA) approval of its new drug application for AMVUTTRA™ (vutrisiran). This RNAi therapeutic is indicated for the treatment of the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients. AMVUTTRA™ offers a subcutaneous injection administered quarterly, providing a convenient treatment option for patients suffering from this rare and progressive disease. The approval of AMVUTTRA™ represents a key milestone for Alnylam, expanding its portfolio of RNAi therapeutics and addressing an unmet medical need in hATTR amyloidosis. This new indication is expected to contribute to the company's revenue growth and solidify its position as a leader in the development of genetic medicines. Investors should monitor the commercial launch and uptake of AMVUTTRA™ as it becomes available to patients.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (May 23, 2022)
This 8-K filing from Alnylam Pharmaceuticals, Inc. reports the outcomes of its 2022 Annual Meeting of Stockholders held on May 18, 2022. Key to investors, the meeting saw the re-election of three Class III directors, indicating continued confidence in the board's leadership and strategic direction. The approval of the Amendment and Restatement of the Company's 2018 Stock Incentive Plan is also a significant event, suggesting ongoing efforts to retain and incentivize key personnel, which is crucial for the company's long-term growth and innovation in the competitive biopharmaceutical landscape. Furthermore, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2022, a standard but important procedural step that reinforces financial transparency and accountability. The advisory vote to approve the compensation of named executive officers also passed, suggesting alignment between shareholder interests and executive remuneration. Overall, the results of the annual meeting indicate strong shareholder support for the company's governance and executive team.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Apr 28, 2022)
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on April 28, 2022, to announce its first-quarter 2022 financial results. While the filing itself doesn't contain the detailed financial figures, it references a press release (Exhibit 99.1) which provides the key performance indicators and operational updates for the period ending March 31, 2022. Investors should refer to this press release for specific revenue, net income/loss, and earnings per share data, as well as any commentary on the company's commercial performance and pipeline development. The primary purpose of this 8-K is to formally disseminate the quarterly financial results. Investors should pay close attention to the metrics discussed in the accompanying press release, particularly those related to the sales performance of its marketed products, progress in clinical trials for its pipeline assets, and any updates on strategic partnerships or regulatory milestones. This information is crucial for assessing the company's financial health and its future growth prospects.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Apr 5, 2022)
This 8-K filing by Alnylam Pharmaceuticals, Inc. announces the resignation of Dr. Steven M. Paul from its Board of Directors, effective April 16, 2022. The company states that Dr. Paul's departure is not due to any disagreements regarding company operations, policies, or practices. Concurrent with his resignation, the Board's size will be reduced from eleven to ten members. Following Dr. Paul's departure, Colleen F. Reitan will join the People, Culture and Compensation (PC&C) Committee, while Amy W. Schulman and Olivier Brandicourt will continue their roles on the committee.
ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Apr 4, 2022)
Alnylam Pharmaceuticals announced on April 4, 2022, that the U.S. Food and Drug Administration (FDA) has extended the review period for its New Drug Application (NDA) for vutrisiran. This extension, pushing the Prescription Drug User Fee Act (PDUFA) action date to July 14, 2022, is for three months. The delay is attributed to the need for FDA review of an amendment to the submission, which addresses a pending inspection classification at a third-party secondary packaging and labeling facility. A new facility has been identified and added to the submission, necessitating this additional review time. Importantly, the company emphasized that no inspection observations were directly related to vutrisiran itself, nor has the FDA requested any additional clinical data. This suggests the delay is procedural, related to the packaging and labeling process rather than the drug's efficacy or safety profile. Investors should monitor the updated PDUFA date closely for potential approval of vutrisiran.